Clinic evaluation within the next few months and then the start of clinic revenue.....RAP seem to have done a lot of work during the few months of integration, Medgate with their 20 years of experience look to be more advanced then Coviu in terms of bringing the product to the market because Europe is way more a head in telehealth than Australia.
"During the integration process, ResApp and Medgate worked collaboratively to conduct comprehensive clinical and technical reviews of ResApp’s technology, detailed mapping of the appropriate user journeys for patients with respiratory disease symptoms, usability testing to deliver a seamless integration pathway, the introduction of automated processes to enhance the patient experience and the development of comprehensive training resources for clinical on boarding to maximise clinician confidence"
RAP Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held
